Novelion Therapeutics Inc. (NVLN) Financial Statements (2025 and earlier)

Company Profile

Business Address C/O NORTON ROSE FULBRIGHT
VANCOUVER, BC V6B 0M3
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2019
MRQ
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 45,15455,430108,927141,824155,908118,521
Cash and cash equivalent 45,15455,430108,927141,824155,908118,521
Restricted cash and investments  253390   
Receivables 28,91222,1919,3393014104,590
Inventory, net of allowances, customer advances and progress billings 12,74515,88674,721  
Inventory 12,74515,88674,721   
Income taxes receivable77
Other undisclosed current assets 15,73211,183(27,241)6111,05338,636
Total current assets: 102,543104,943166,136142,736157,371161,824
Noncurrent Assets
Inventory, Noncurrent 36,20233,94059,003   
Property, plant and equipment 1,5852,9204,1594301,0001,866
Long-term investments and receivables    2,0002,000 
Accounts and financing receivable, after allowance for credit loss    2,0002,000 
Intangible assets, net (including goodwill) 200,176225,272250,324  
Intangible assets, net (excluding goodwill) 200,176225,272250,324   
Other noncurrent assets 1,2092,2471,160   
Other undisclosed noncurrent assets      177
Total noncurrent assets: 239,172264,379314,6462,4303,0002,043
TOTAL ASSETS: 341,715369,322480,782145,166160,371163,867
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 50,20755,63854,7893,4834,6074,107
Employee-related liabilities     1,136 
Accounts payable 6,01213,80017,6091,6561,9432,609
Accrued liabilities 44,19541,83837,1801,8271,5281,498
Debt 73,677     
Deferred compensation liability     392265
Estimated litigation liability   64,010   
Other undisclosed current liabilities 286,5048,596  (1,528)(135)
Total current liabilities: 410,38864,234118,7993,4833,4714,237
Noncurrent Liabilities
Long-term debt and lease obligation  258,538225,584   
Long-term debt, excluding current maturities  258,538225,584   
Liabilities, other than long-term debt 7965966123423881,846
Liability for uncertainty in income taxes   3813423881,846
Other liabilities 796596231   
Other undisclosed noncurrent liabilities 19,39131,016    
Total noncurrent liabilities: 20,187290,150226,1963423881,846
Total liabilities: 430,575354,384344,9953,8253,8596,083
Equity
Equity, attributable to parent (88,860)14,938135,787141,341156,512157,784
Common stock 552,506551,925551,259475,333467,034466,229
Additional paid in capital 79,29573,18569,14997,37797,83895,844
Accumulated other comprehensive income 101,640103,802102,587102,969102,969102,969
Accumulated deficit (822,301)(713,974)(587,208)(534,338)(511,329)(507,258)
Total equity: (88,860)14,938135,787141,341156,512157,784
TOTAL LIABILITIES AND EQUITY: 341,715369,322480,782145,166160,371163,867

Income Statement (P&L) ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 130,432138,43813,574   
Revenue, net138,43813,574   
Cost of revenue (59,697)(77,220)(5,971)  (1,121)
Cost of product and service sold (59,697)(77,220)(5,971)   
Gross profit: 70,73561,2187,603  (1,121)
Operating expenses (120,802)(148,016)(44,309)(25,411)(31,338)(27,369)
Other undisclosed operating income    2,06627,509 
Operating loss: (50,067)(86,798)(36,706)(23,345)(3,829)(28,490)
Nonoperating income (expense) (1,830)(292)(1,999)358(368)3,251
Gain (loss), foreign currency transaction, before tax    32(62)(32)
Other nonoperating income (expense) (1,830)(292)(1,999)49115207
Interest and debt expense (4,333)     
Other undisclosed loss from continuing operations before equity method investments, income taxes   (13,700)   
Loss from continuing operations before equity method investments, income taxes: (56,230)(87,090)(52,405)(22,987)(4,197)(25,239)
Other undisclosed loss from continuing operations before income taxes (50,498)(39,037)    
Loss from continuing operations before income taxes: (106,728)(126,127)(52,405)(22,987)(4,197)(25,239)
Income tax expense (benefit) (1,599)(583)(465)(22)192(599)
Loss from continuing operations: (108,327)(126,710)(52,870)(23,009)(4,005)(25,838)
Loss before gain (loss) on sale of properties: (108,327)(126,710)(52,870)(23,009)(4,071)(24,871)
Income (loss) from discontinued operations     (66)967
Net loss available to common stockholders, diluted: (108,327)(126,710)(52,870)(23,009)(4,071)(24,871)

Comprehensive Income ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (108,327)(126,710)(52,870)(23,009)(4,071)(24,871)
Other comprehensive loss   (382)   
Comprehensive loss: (108,327)(126,710)(53,252)(23,009)(4,071)(24,871)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (2,162)1,215    
Comprehensive loss, net of tax, attributable to parent: (110,489)(125,495)(53,252)(23,009)(4,071)(24,871)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: